Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

In This Article:

SAN DIEGO, November 08, 2024--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results.

Corporate Highlights

  • Completed GMP manufacture of Gemini clinical drug supply

  • Received net proceeds of $3.8 million from the exercise of warrants in August 2024

  • Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers

"The Revelation team continues to make significant progress on the advancement of Gemini," said James Rolke, Chief Executive Officer of Revelation. "We look forward to the anticipated acceptance of our IND by the FDA and building on this momentum with the start of our Phase 1b study in CKD patients in the United States."

Results of Operations

As of September 30, 2024, Revelation had $6.5 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The decrease in cash and cash equivalents was primarily due to cash used for operating activities and the Lifesci Capital judgment, offset by net cash received from financing activities. Based on current operating plans and projections, Revelation believes that its current cash and cash equivalents are sufficient to fund operations into 2025.

Revelation’s net cash used for operating activities for the nine months ended September 30, 2024 was $14.6 million compared to net cash used for operating activities of $5.3 million for the same period in 2023. Revelation’s net loss for the three months ended September 30, 2024 was $2.2 million, or $0.84 basic and diluted net loss per share compared to a net loss of $2.6 million, or $9.94 basic and diluted net loss per share for the same period in 2023. Revelation’s net loss for the nine months ended September 30, 2024 was $13.3 million, or $7.38 basic and diluted net loss per share compared to net income of $2.1 million, or $9.62 basic net earnings per share and $9.38 diluted net earnings per share for the same period in 2023, respectively.

About Gemini

Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®) for systemic administration. It is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of post-surgical infection (GEMINI-PSI program), and as a pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program). In addition, Gemini may be a treatment to stop or slow the progression of chronic kidney disease (GEMINI-CKD program). Revelation believes Gemini works through trained immunity, which redirects and attenuates the innate immune response to external stress (infection, trauma, etc.). Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications.